Australian biotech HaemaLogix has posted phase 2b data that show its monoclonal antibody “significantly” improves response rates for multiple myeloma patients when paired with Revlimid.
Median overall survival was not reached, with two of the patients remaining on the therapy and continuing to respond to the treatment, the biotech noted.
No treatment-related hematological toxicities or serious adverse effects were reported in the trial, the biotech added.
The company already suspected that KappaMab had a “synergistic mechanism of action” with Revlimid, and this was the spur for the latest trial. Up next will be a study testing the monoclonal antibody with Bristol Myers’ Pomalyst, also known as pomalidomide, another multiple myeloma mainstay.
While KappaMab is the company’s most advanced asset, the biotech’s preclinical pipeline includes a KMA-targeting CAR-T therapy alongside other potential antibody and cell therapies.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.